DEP®cabazitaxel, DEP®docetaxel, and DEP®irinotecan, are dendrimer versions of widely used chemotherapeutic drugs that have demonstrated improvements in efficacy and tolerability in Phase 2 clinical trials. Additionally, Starpharma has a preclinical pipeline of DEP®radiopharmaceuticals and ...
DEP SN38 is a water-soluble version of SN38, the active metabolite of irinotecan, attached to a dendrimer, so avoiding usual metabolic pathways of conventional irinotecan (c-IRI). This phase 1/2 (P1/2) trial evaluated safety, tolerability and efficacy of DEP SN38 in pts with advanced solid...
Starpharma开发的DEP®卡巴它赛、DEP®多西他赛和DEP®伊立替康(Irinotecan)等DEP®产品均已进入2期临床阶段,以DEP® cabazitaxel(卡巴它赛)为例。 DEP® cabazitaxel水溶性好,不含聚山梨酯-80,临床给药无需使用类固醇类药物或粒细胞集落刺激因子(G-CSF)进行预处理,可降低cabazitaxel严重骨髓毒性风险。 在...
应用依立替康(Irinotecan。CPT-11),也叫开普拓时,基因检测找出不适合该药的人群,可以避免致命性腹泻及严重的中性粒细胞减少。 本实验室建立起了多个基因,不同水平的检测方法,推出了适合化疗、靶向治疗等不同肿瘤治疗的选择性套餐服务,并将多种检测方法(基因测序法,ARMs法,荧光定量PCR法以及GeneMapper等)很好的结合...
Starpharma开发的DEP®卡巴它赛、DEP®多西他赛和DEP®伊立替康(Irinotecan)等DEP®产品均已进入2期临床阶段,以DEP® cabazitaxel(卡巴它赛)为例。 DEP® cabazitaxel水溶性好,不含聚山梨酯-80,临床给药无需使用类固醇类药物或粒细胞集落刺激因子(G-CSF)进行预处理,可降低cabazitaxel严重骨髓毒性风险。